Table 5 Demographics, MV, and vasoactive use differences between dead and discharged patients
From: Role of immature granulocytes in monitoring sepsis treatment
Discharged N:54(%) | Dead N:33(%) | |||
|---|---|---|---|---|
Gender | Female | 30 (55.6%) | 11 (33.3%) | 0.044 |
Male | 24 (44.4%) | 22 (66.7%) | ||
DM | 19 (35.2%) | 9 (27.3%) | 0.443 | |
HT | 32 (59.3%) | 15 (45.5%) | 0.210 | |
Cardiac disease | 22 (40.7%) | 8 (24.2%) | 0.116 | |
COPD | 11 (20.4%) | 9 (27.3%) | 0.458 | |
Malignancy | 5 (9.3%) | 10 (30.3%) | 0.012 | |
CKD | 7 (13%) | 4 (12.1%) | 0.909 | |
Neurologic disease | 23 (42.6%) | 9 (27.3%) | 0.150 | |
Vasoactive drugs | 26 (48.1%) | 16 (48.5%) | 0.979 | |
MV | 39 (72.2%) | 27 (81.8%) | 0.310 | |
AB changed | 26 (48.1%) | 23 (69.7%) | 0.049 |